Breast Neoplasms, Stomach Neoplasms
Conditions
Keywords
HER2, breast cancer, ADC, antibody drug conjugate, elevated HER2 expression
Brief summary
This is a 2-part, Phase 1 FIH study with Phase 1a designed to determine the maximum tolerated dose (MTD)/recommended Phase 2 dose (RP2D) in subjects with metastatic cancers with a human epidermal growth factor receptor 2 (HER2) test result that is in situ hybridization (ISH) positive (+) or immunohistochemistry (IHC) 3+ or 2+, and Phase 1b designed to assess anticancer activity and safety in three expansion cohorts: two different advanced breast cancer expansion cohorts (namely, for tumors that test as HER2 ISH positive or IHC3+ and for tumors that test as HER2 ISH negative with IHC 2+), and one advanced gastric cancer expansion cohort (for tumors that test as HER2 ISH positive or IHC3+).
Interventions
DRUGARX788
ARX788, an antibody drug conjugate
Sponsors
Ambrx, Inc.
Zhejiang Medicine Co., Ltd.
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Life expectancy \>12 weeks. 2. BMI is between 18 to 32 kg/m2 3. Subjects whose advanced cancer has failed treatment or whose cancer has progressed following available standard therapy or for whom such therapy is not acceptable to the subject. Subjects whose tumor tissue local laboratory results are HER2 ISH positive or IHC3+ must have been previously treated with a HER2 targeting therapy (e.g. trastuzumab, in the country or region where such therapies are available and part of standard of care), or have failed SOC therapy. Subjects who have been previously treated with a HER2 targeting therapy such as trastuzumab or ado-trastuzumab emtansine are eligible. 4. Disease measurability: Phase 1a: measureable or non-measureable disease; Phase 1b: disease must be measureable (per RECIST v1.1) (subjects with non-measureable disease are not eligible for Phase 1b). 5. Histopathologic evidence of breast cancer based upon pathologist's report. 6. Tumor tissue local laboratory HER2 testing results (clinical pathology report) based on FDA or other regulatory agency approved, validated or commercially available IHC or ISH HER2 assay. Pre-screening for HER2 is allowed only for subjects with breast and gastric cancer, where applicable. Subjects with other types of cancer must have previously tested for HER2 status by HER2 IHC or ISH assay. 1) Phase 1a: ISH positive or IHC 2+ or 3+. 2) Phase 1b: Cohort 1: advanced breast cancer, ISH positive or IHC 3+; Cohort 2: advanced breast cancer, ISH negative with IHC 2+; and Cohort 3: advanced gastric cancer, ISH positive or IHC 3+. 7. Local pathology laboratory determination of HER2 status will be accepted, provided that the local laboratory is an accredited site for HER2 testing. In Phase 1b, if the local laboratory was not accredited at the time of testing, an adequate tumor tissue sample is required for central pathology laboratory HER2 testing. The tissue sample may be provided as 10 pre-cut unstained slides or a tumor block. 8. Eastern Cooperative Oncology Group Performance Status of 0 to 1. 9. Acute toxicities from any prior therapy, surgery, or radiotherapy must have resolved to Grade 0 or 1 as per the NCI-CTCAE v 4.03. 10. The last dose of prior anticancer therapy must have been administered at least 28 days prior to the first dose of the IMP. 11. Adequate bone marrow function defined by absolute neutrophil count of ≥1.5×109/L, platelet count of ≥100.0×109/L, and hemoglobin of ≥9.0 g/dL. 12. Adequate hepatic function defined by serum total bilirubin ≤1.5 × upper limit of normal (ULN), aspartate aminotransferase/alanine aminotransferase ≤2.5 × ULN (or ≤5 × ULN in subjects with liver metastases). 13. Adequate renal function assessed by serum creatinine within reference lab normal limits and creatinine clearance (by Chronic Kidney Disease Epidemiology \[CKD-EPI\] Collaboration equation) ≥60 mL/min. 14. Adequate cardiac function as assessed by cardiac troponin I within normal range; left ventricular ejection fraction ≥ 50% or institutional lower limit of normal; cumulative anthracycline dose \<360 mg/m2 doxorubicin or equivalent. 15. Willing and able to understand and sign an informed consent inform and to comply with all aspects of the protocol. 16. Female subjects must be surgically sterile, or have a monogamous partner who is surgically sterile, or at least 2 years postmenopausal, or who commits to use an acceptable form of birth control (defined as the use of an intrauterine device, a barrier method with spermicide, condoms, any form of hormonal contraceptives, or abstinence) for the duration of the study and for 3 months following the last dose of study treatment. 17. Male subjects must be sterile (biologically or surgically) or commit to the use of a reliable method of birth control (condoms with spermicide) for the duration of the study.
Exclusion criteria
Any subject who meets any of the following criteria should be excluded from the study: 1. History of allergic reactions to any component of the ARX788. 2. 2\. History of seizure disorder. 3. History of unstable central nervous system (CNS) metastases or seizure disorder related to the malignancy; however, those subjects who were treated for prior CNS metastases and who are asymptomatic may participate in the study as long as they are not receiving treatment with steroids. 4. History of congestive heart failure, unstable angina pectoris, unstable atrial fibrillation, or cardiac arrhythmia. 5. Grade 2 to 4 peripheral neuropathy (NCI CTCAE v 4.03). 6. Non-manageable electrolyte imbalances including hypokalemia, hypocalcemia, or hypomagnesemia (Grade 2 or greater based on NCI CTCAE v 4.03). 7. Any uncontrollable intercurrent illness, infection, or other conditions that could limit study compliance or interfere with assessments. 8. Exposure to any other investigational or commercial anticancer agents or therapies administered with the intention to treat malignancy within 28 days before the first dose of the IMP. 9. Significant surgical intervention within 21 days of the first dose of the IMP or with ongoing post-operative complications if more than 21 days. 10. Radiotherapy administrated less than 21 days prior to the first dose of the IMP, or localized palliative radiotherapy administered less than 7 days prior to the first dose of the IMP, or radiotherapy induced toxicity of Grade 2 or greater based on NCI CTCAE v 4.03. 11. Pregnancy or breast feeding. 12. Refusal to use effective methods of contraception (see inclusion criteria for details). 13. Legal incapacity/limited legal capacity for providing informed consent.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Maximum tolerated dose of ARX788 | 12 months | Determine highest dose level at which less than 2 of 6 subjects experience a dose limiting toxicity. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of subjects with Adverse Events | 30 months | Safety and tolerability of ARX788 as measured by all adverse events, hematology, blood chemistry, vital signs, electrocardiogram, and physical exam. |
| Area under the plasma concentration versus time curve (AUC) of ARX788 after infusion | 30 months | Pharmakokinetic characteristics of ARX788 for infusion Cycle 1 and Cycle 3 |
| Half-life of ARX788 after infusion | 30 months | Pharmakokinetic characteristics of ARX788 for infusion Cycle 1 and Cycle 3 |
| Number of participants with tumor response to ARX788 administration | 18 months | — |
| Number of subjects developed anti-ARX788 antibody | 30 months | Immunogenicity profile assessment |
Countries
Australia, New Zealand
Outcome results
None listed